Streetbeat News

Stock Prices

CVS

Deep-pocketed investors have shown a bullish trend in CVS Health (NYSE:CVS) options trading, with a significant portion of activity leaning towards bullish sentiments. Benzinga's options scanner revealed 12 extraordinary activities, with a price target range from $50.0 to $72.0. The trading includes both puts and calls, with the largest trades indicating a mix of bullish and bearish sentiments. CVS Health, a major healthcare services provider, has seen its stock price slightly down with analysts giving mixed reviews but generally positive price targets.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 4:01 pm

RVTY

Analysts have updated their ratings and price targets for Revvity (NYSE:RVTY), showing a positive shift in sentiment with an average 12-month price target of $123.25, up 13.59% from the previous $108.50. The company, operating in diagnostics and discovery/analytical solutions, faces a revenue decline of -6.11% over the last 3 months but maintains a strong net margin of 11.29%. Despite challenges in revenue growth and ROE, Revvity's prudent debt management and profitability are highlighted.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 4:01 pm

NKE

Analyst ratings for Nike (NYSE:NKE) over the last quarter show a mix of bullish to bearish sentiments among 29 analysts, with a shift towards more conservative ratings in the last 30 days. The average 12-month price target for Nike is now $114.28, down 7.84% from the previous target, reflecting a cautious outlook from analysts. Recent actions include both downgrades and maintenance of ratings, with price targets adjusted accordingly. Nike's financial performance remains strong, with positive revenue growth, high net margin, and effective debt management, positioning it well in the athletic footwear and apparel industry.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 4:00 pm

JBL

Over the past 10 years, Jabil (NYSE:JBL) has produced an average annual return of 21.09%, outperforming the market by 10.6% annually. With a current market capitalization of $14.33 billion, a $1000 investment in JBL stock 10 years ago would be worth $6,761.24 today.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 4:00 pm

PDD

$100 invested in PDD Holdings (NASDAQ:PDD) 5 years ago would now be worth $525.75, showcasing an annualized return of 39.62% and outperforming the market by 28.05%. PDD Holdings currently has a market cap of $174.94 billion.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 4:00 pm

FTXN

IEO

MPC

MPLX

Marathon Petroleum Corporation (NYSE:MPC) shares fell after reporting Q1 FY24 results with revenue of $33.211 billion, surpassing estimates but with a decline in adjusted EBITDA to $3.26 billion from $5.22 billion year-over-year. Refining & Marketing segment adjusted EBITDA also dropped significantly due to lower market crack spreads and throughputs. Despite this, adjusted EPS was $2.78, above consensus. The company announced a $5 billion share repurchase authorization, adding to an existing $3.8 billion, and returned $2.2 billion through share repurchases and $299 million via dividends in Q1. MPLX LP (NYSE:MPLX), in which Marathon Petroleum holds a significant interest, reported earnings per limited partner unit of $0.98 on sales of $2.85 billion, missing estimates. MPC shares are down 6.6%.

Portfolio Pulse from Lekha Gupta

April 30, 2024 | 3:59 pm

CECO

CECO Environmental shares are trading lower following the announcement of Q1 sales results that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 3:57 pm

AMGN

SDZNY

SDZXF

Sandoz AG has settled its patent litigation with Amgen Inc over the bone disorder drug denosumab, allowing for the launch of biosimilars Jubbonti and Wyost by May 31, 2025. The settlement will not affect Sandoz's 2024 guidance, and these biosimilars have received FDA approval. Amgen's Prolia, a reference medicine for these biosimilars, received a serious warning from the FDA in January due to risks of low calcium levels in certain patients. AMGN shares dropped by 0.91% following the news.

Portfolio Pulse from Vandana Singh

April 30, 2024 | 3:55 pm

ETWO

E2open Parent Holdings' shares surged following the announcement of Q4 financial results that exceeded expectations, along with the issuance of optimistic revenue guidance for FY25.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 3:54 pm

SPY

Ahead of the Federal Open Market Committee meeting, Wall Street braces for the Fed's stance on interest rates amid higher-than-expected inflation readings. While the Fed is expected to maintain rates, focus shifts to the potential for future rate cuts. Recent inflation data, including the PCE price index, indicates robust inflation, leading analysts to predict cautious Fed actions. Bank of America and Citigroup offer divergent views on the extent of rate cuts by the end of 2024. The SPDR S&P 500 ETF Trust (SPY) saw a slight increase ahead of the meeting, reflecting investor sentiment.

Portfolio Pulse from Piero Cingari

April 30, 2024 | 3:51 pm